| "Hjälper kvinnor att följa sin ägglossning på ett smartare sätt" | 
Key takeaways
- Diagnosis of polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS) requires two of three features, not all three, so different people meet it through different combinations.
- Each feature also varies in degree, which widens the range of presentations further.
- Research groups these combinations into categories, but what they mean for an individual’s long-term outcomes is not yet well understood.
- Two people with the same diagnosis can have genuinely different experiences of it.
- Which combination you meet the criteria through is a clinical question, not something to work out from a list.
PMOS presents differently between people because diagnosis requires two of three features rather than all three, so different combinations satisfy the criteria. Each feature also varies in degree. Research does group these combinations into categories, but what those categories mean for any individual’s outcomes remains an open question.
Why doesn’t my PMOS look like someone else’s?
Because the diagnostic criteria allow for it by design.
Diagnosis in adults requires two of three features, after other causes are excluded (DOI: 10.1210/clinem/dgad463):1
- Clinical or biochemical hyperandrogenism
- Ovulatory dysfunction
- Polycystic ovarian morphology on ultrasound, or elevated anti-Müllerian hormone
Because only two are required, several different combinations satisfy the criteria. Someone with irregular cycles and androgen symptoms has it. So does someone with androgen symptoms and the ovarian appearance but regular cycles. So does someone with all three.
They have the same diagnosis and can have very little in common day to day.
Variation within each feature, not just between combinations
The combination is only part of it. Each individual feature also varies in degree.
Androgen effects
Androgen effects vary because tissue sensitivity to androgens differs between people, so similar hormone levels can produce noticeably different symptoms.2
Cycle disruption
Cycle disruption ranges from mild irregularity to long gaps between periods, and the guideline’s definition of irregular changes with how long it has been since a first period.1
Ovarian appearance
Ovarian appearance is a count, and counts sit anywhere along a range rather than falling into two boxes.1
So two people can share a combination and still not recognise each other’s experience.
Does research group these into types?
Yes, and this is where it is worth being careful about what is known.
Because two of three features are required, there are four possible combinations, and the research literature labels them A through D as a shorthand for describing study populations.2 The labelling originates in the diagnostic criteria themselves rather than in any separate clinical framework.
What those categories mean for an individual is much less settled. Differences in long-term outcomes between them are not yet fully understood, and studies looking at outcomes by category have produced inconsistent results.2 Some work suggests the combinations involving androgen excess carry a different metabolic picture from the one that does not; other work complicates that.
The categories are a research tool for describing groups. They are not a staging system, they do not rank severity, and they are not a diagnosis you receive. If you have seen confident statements online about what a particular letter means for your health, they are running ahead of the evidence.
Why this matters more than it sounds
Three practical consequences.
- Comparison is unreliable. Someone else’s experience of this condition, including in support communities, may not tell you much about yours. That cuts both ways: worse than you does not mean you are fine, and better than you does not mean you are failing.
- Advice does not generalise cleanly. What was appropriate for another person depended on their combination, their degree of each feature, and everything else about them.
- You may have been assessed against the wrong picture. The stereotypical presentation is not the common presentation, it is one presentation. If your experience does not match what you have read, that is a reason to describe yours clearly rather than to doubt it.
What this means for talking to a clinician
The useful thing is not to arrive with a category. It is to describe what you actually experience.
Which features you meet the criteria through is worked out clinically, from your history, examination and any tests, not from a checklist. A clinician can tell you which apply to you and what follows from that, which is a more useful conversation than a label.
Worth knowing: where irregular cycles and hyperandrogenism are both present, an ultrasound is not required for diagnosis.1 And ovulatory dysfunction can occur in people whose cycles look regular, in which case hormonal assessment is how it is assessed.1
What this means for tracking with Premom
Premom is an ovulation tracking application. It is not intended to diagnose, treat, cure, or prevent any disease, including PMOS. The information provided is for educational purposes and should not replace consultation with a healthcare provider.
An app cannot tell you which features you have. Two of the three are established through clinical assessment and tests it has no access to.
What a record of cycle dates across months contributes is information about the third (the pattern of your cycles) in a form that is easier to bring to an appointment than to recall. That is one strand of one feature, which is worth being clear about.
When to talk to a clinician
The information here is general and is not a basis for self-diagnosis. Speak with a clinician if:
- Your experience does not match what you have read and you have not been assessed
- You have a diagnosis but do not know which features you meet it through
- Your cycles are consistently long or vary widely from month to month
- You have symptoms that concern you, whether or not they fit a pattern you recognise
Frequently asked questions
That is a clinical question rather than something to work out from a list. Which features you meet the criteria through comes from your history, examination and any tests, and a clinician can tell you which apply to you and what follows from it.
Research groups the combinations into categories for describing study populations, but what they mean for an individual’s long-term outcomes is not yet well understood, and studies have produced inconsistent results. They are not a severity ranking.
Because diagnosis requires two of three features rather than all three, and each feature also varies in degree. Two people with the same diagnosis can have very little in common day to day.
Features vary in degree and ovarian appearance can change, so a picture taken at one point is not necessarily permanent. What that means for you is a question for a clinician who can see your history.
It is unreliable in both directions. Someone whose experience is harder than yours does not mean you are fine, and someone whose experience is easier does not mean you are failing at something.
About PMOS
Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome (PMOS) by international consensus published in The Lancet on 12 May 2026.3 A three-year transition runs to 2028, and both names remain in clinical use. Diagnostic criteria did not change, and an existing PCOS diagnosis remains valid.
Reported prevalence varies with the criteria applied; the 2023 International Evidence-Based Guideline reports 10–13% (DOI: 10.1210/clinem/dgad463).1
References
- Teede HJ, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. DOI 10.1210/clinem/dgad463 · PMID 37580314. Recommendation 1.1.1 (irregular cycle definitions).
- Strauss JF III, Barbieri RL, eds. Yen & Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. 8th ed. Elsevier; 2019. ISBN 978-0-323-47912-7.
- Teede HJ, et al. The Lancet, 12 May 2026. DOI 10.1016/S0140-6736(26)00717-8 · PMID 42119588.
